1 |
LAHOZ C, MOSTAZA J M. Familial hypertriglyceridemia/polygenic hypertrigliceridemia[J]. Clin Investig Arterioscler, 2021, 33(Suppl 2): 37-42.
|
2 |
CARRASQUILLA G D, CHRISTIANSEN M R, KILPELÄINEN T O. The genetic basis of hypertriglyceridemia[J]. Curr Atheroscler Rep, 2021, 23(8): 39.
|
3 |
CRUZ-BAUTISTA I, HUERTA-CHAGOYA A, MORENO-MACÍAS H, et al. Familial hypertriglyceridemia: an entity with distinguishable features from other causes of hypertriglyceridemia[J]. Lipids Health Dis, 2021, 20(1): 14.
|
4 |
诸骏仁, 高润霖, 赵水平, 等. 中国成人血脂异常防治指南(2016年修订版)[J]. 中国循环杂志, 2016, 31(10): 937-953.
|
|
ZHU J R, GAO R L, ZHAO S P, et al. The guidelines for prevention and treatment of dyslipidemia in Chinese adults (revised edition 2016)[J]. Chin J Cardiol, 2016, 44(10): 833-853.
|
5 |
KULKARNI K R. Cholesterol profile measurement by vertical auto profile method[J]. Clin Lab Med, 2006, 26(4): 787-802.
|
6 |
刘维娟, 周珊珊, 何津春, 等. 家族性高三酰甘油血症诊断标准及鉴别诊断[J]. 医学综述, 2014, 20(17): 3089-3091.
|
|
LIU W J, ZHOU S S, HE J C, et al. Diagnostic criteria and differential diagnosis of familial hypertriglyceridemia[J]. Med Recapitulate, 2014, 20(17): 3089-3091.
|
7 |
梁纯子, 朱满, 涂建成. VAP检测血浆脂蛋白亚组分的新进展及应用分析[J]. 检验医学, 2019, 34(1): 76-81.
|
|
LIANG C Z, ZHU M, TU J C, Research progress of VAP in determining plasma lipoprotein subfractions[J]. Lab Med, 2019, 34(1): 76-81.
|
8 |
PAN L, YANG Z H, WU Y, et al. The prevalence, awareness, treatment and control of dyslipidemia among adults in China[J]. Atherosclerosis, 2016, 248: 2-9.
|
9 |
张娜, 张海燕, 郭晓红, 等. 中国近十年急性胰腺炎病因变化特点的Meta分析[J]. 中华消化病与影像杂志(电子版), 2016, 6(2): 71-75.
|
|
ZHANG N, ZHANG H Y, GUO X H, et al. Changes of etiology in acute pancreatitis in recent 10 years in China: Meta-analysis[J]. Chin J Digest Med Imageol (Electronic Edition), 2016, 6(2): 71-75.
|
10 |
OLESEN S S, HARAKOW A, KROGH K, et al. Hypertriglyceridemia is often under recognized as an aetiologic risk factor for acute pancreatitis: a population-based cohort study[J]. Pancreatology, 2021, 21(2): 334-341.
|
11 |
SHAIK A, ROSENSON R S. Genetics of triglyceride-rich lipoproteins guide identification of pharmacotherapy for cardiovascular risk reduction[J]. Cardiovasc Drugs Ther, 2021, 35(3): 677-690.
|
12 |
中华医学会心血管病学分会循证医学评论专家组, 中国老年学学会心脑血管病专业委员会. 甘油三酯增高的血脂异常防治中国专家共识[J]. 中华心血管病杂志, 2011, 39(9): 793-796.
|
|
Expert Group of Evidence-based Medicine Review of Cardiovascular Credit Association of Chinese Medical Association, Professional Committee of Cardiovascular and Cerebrovascular Diseases of Chinese Gerontology Society. Consensus of Chinese experts on the prevention and treatment of dyslipidemia caused by elevated triglycerides[J]. Chin J Cardiol, 2011, 39(9): 793-796.
|
13 |
FARUKHI Z, MORA S. Is it time to abandon fasting for routine lipid testing? [J]. Clevel Clin J Med, 2017, 84(12): 919-922.
|
14 |
JUSTESEN J M, ALLIN K H, SANDHOLT C H, et al. Interactions of lipid genetic risk scores with estimates of metabolic health in a Danish population[J]. Circ Cardiovasc Genet, 2015, 8(3): 465-472.
|
15 |
REINER Ž. Triglyceride-rich lipoproteins and novel targets for anti-atherosclerotic therapy[J]. Korean Circ J, 2018, 48(12): 1097-1119.
|
16 |
LANGLOIS M R, CHAPMAN M J, COBBAERT C, et al. Quantifying atherogenic lipoproteins: current and future challenges in the era of personalized medicine and very low concentrations of LDL cholesterol. A consensus statement from EAS and EFLM[J]. Clin Chem, 2018, 64(7): 1006-1033.
|
17 |
HALLÉN J, SREEHARAN N. Development of triglyceride-lowering drugs to address residual cardiovascular risk: strategic and clinical considerations[J]. Eur Heart J Cardiovasc Pharmacother, 2018, 4(4): 237-242.
|
18 |
NORDESTGAARD B G. Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights from epidemiology, genetics, and biology[J]. Circ Res, 2016, 118(4): 547-563.
|
19 |
ALLAIRE J, VORS C, COUTURE P, et al. LDL particle number and size and cardiovascular risk: anything new under the sun? [J]. Curr Opin Lipidol, 2017, 28(3): 261-266.
|
20 |
MARTIN S S, KHOKHAR A A, MAY H T, et al. HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the Lipoprotein Investigators Collaborative[J]. Eur Heart J, 2015, 36(1): 22-30.
|
21 |
ZHAO M, GUO Z H, JIA G W, et al. Influencing factors of coronary artery Stenosis in patients with stable coronary heart disease and a correlation analysis[J]. Am J Transl Res, 2021, 13(8): 9522-9529.
|
22 |
SINGH A, PUHAN R, PRADHAN A, et al. Small dense low-density lipoprotein for risk prediction of acute coronary syndrome[J]. Cardiol Res, 2021, 12(4): 251-257.
|
23 |
YU Y, WANG L, ZHU X, et al. Sodium ozagrel and atorvastatin for type 2 diabetes patients with lacunar cerebral infarction[J]. World J Diabetes, 2021, 12(12): 2096-2106.
|